-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Tjbmltk1cf9VMz+zGYrn0ymd8ygpfilKWJgc70Onjwcn3LmlsYUInXtPdCE6bo8X tY41YQQ5mFyPU42udKiGeg== 0001022079-04-000008.txt : 20040105 0001022079-04-000008.hdr.sgml : 20040105 20040105161711 ACCESSION NUMBER: 0001022079-04-000008 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20040101 FILED AS OF DATE: 20040105 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MALCOLM AVE CITY: TETERBORO STATE: NJ ZIP: 07608 BUSINESS PHONE: 2013935000 MAIL ADDRESS: STREET 1: ONE MALCOLM AVE CITY: TETERBORO STATE: NJ ZIP: 07601 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GRANT WILLIAM R CENTRAL INDEX KEY: 0001016359 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 04505185 BUSINESS ADDRESS: STREET 1: 610 FIFTH AVENUE 5TH FLOOR STREET 2: C/O GALEN ASSOCIATES CITY: NEW YORK STATE: NY ZIP: 10020 BUSINESS PHONE: 2122184990 MAIL ADDRESS: STREET 1: C/O GALEN ASSOCIATES STREET 2: 610 FIFTH AVENUE 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10020 4 1 c0001016359d20040105f4f.xml PRIMARY DOCUMENT X0201 42004-01-0100001022079QUEST DIAGNOSTICS INC DGX0001016359GRANT WILLIAM RONE MALCOLM AVENUETETERBORONJ076081000Stock Options (Right to buy)73.192004-01-014A03190A2004-01-012014-01-01Common Stock319< postTransactionAmounts>319DPursuant to a stockholder agreement between the Issuer and SmithKline Beecham plc (n/k/a GlaxoSmithKline plc.), the reporting person has been elected as a director at the designation of GlaxoSmithKline. The reporting person disclaims beneficial ownership of the shares of the Issuer beneficially owned by GlaxoSmithKline.Leo C. Farrenkopf, Jr.2004-01-05 -----END PRIVACY-ENHANCED MESSAGE-----